The Spanish company will use the funding to accelerate the clinical transition of its LiverAce Combo assay for drug-induced liver injury assessment.
Distinct patterns of SARS-CoV-2 viral dynamics in saliva reveal heterogeneity that cannot be sufficiently explained by conventional clinical characteristics or microRNA profiles alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback